Bank of New York Mellon’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.32M | Buy |
732,616
+177,439
| +32% | +$496K | ﹤0.01% | 2866 |
|
|
2026
Q1 | $1.52M | Buy |
555,177
+6,083
| +1% | +$19.3K | ﹤0.01% | 2962 |
|
|
2025
Q4 | $2.03M | Buy |
549,094
+86,006
| +19% | +$278K | ﹤0.01% | 2825 |
|
|
2025
Q3 | $1.23M | Buy |
463,088
+36,031
| +8% | +$69.7K | ﹤0.01% | 3090 |
|
|
2025
Q2 | $420K | Buy |
427,057
+11,916
| +3% | +$11.9K | ﹤0.01% | 3605 |
|
|
2025
Q1 | $598K | Sell |
415,141
-12,391
| -3% | -$22.8K | ﹤0.01% | 3358 |
|
|
2024
Q4 | $941K | Buy |
427,532
+1,758
| +0.4% | +$4.1K | ﹤0.01% | 3201 |
|
|
2024
Q3 | $703K | Sell |
425,774
-146,549
| -26% | -$296K | ﹤0.01% | 3332 |
|
|
2024
Q2 | $1.27M | Buy |
572,323
+555,382
| +3,278% | +$1.31M | ﹤0.01% | 3057 |
|
|
2024
Q1 | $45.4K | Sell |
16,941
-48,193
| -74% | -$117K | ﹤0.01% | 4089 |
|
|
2023
Q4 | $195K | Buy |
65,134
+37,738
| +138% | +$49K | ﹤0.01% | 3962 |
|
|
2023
Q3 | $26.8K | Sell |
27,396
-162
| -0.6% | -$234 | ﹤0.01% | 4221 |
|
|
2023
Q2 | $38.3K | Sell |
27,558
-257,382
| -90% | -$359K | ﹤0.01% | 4214 |
|
|
2023
Q1 | $453K | Sell |
284,940
-1,346
| -0.5% | -$6.95K | ﹤0.01% | 3539 |
|
|
2022
Q4 | $1.78M | Buy |
286,286
+13,880
| +5% | +$99.3K | ﹤0.01% | 2913 |
|
|
2022
Q3 | $1.82M | Buy |
272,406
+31,217
| +13% | +$214K | ﹤0.01% | 2917 |
|
|
2022
Q2 | $1.53M | Buy |
241,189
+16,967
| +8% | +$96.2K | ﹤0.01% | 2981 |
|
|
2022
Q1 | $1.04M | Buy |
224,222
+112,894
| +101% | +$484K | ﹤0.01% | 3290 |
|
|
2021
Q4 | $557K | Buy |
111,328
+19,279
| +21% | +$154K | ﹤0.01% | 3739 |
|
|
2021
Q3 | $1.11M | Buy |
92,049
+8,292
| +10% | +$121K | ﹤0.01% | 3333 |
|
|
2021
Q2 | $1.77M | Sell |
83,757
-17,535
| -17% | -$422K | ﹤0.01% | 3071 |
|
|
2021
Q1 | $2.84M | Sell |
101,292
-16,725
| -14% | -$493K | ﹤0.01% | 2720 |
|
|
2020
Q4 | $3.07M | Sell |
118,017
-18,056
| -13% | -$541K | ﹤0.01% | 2598 |
|
|
2020
Q3 | $5.06M | Sell |
136,073
-1,406
| -1% | -$55.7K | ﹤0.01% | 2211 |
|
|
2020
Q2 | $7.05M | Buy |
137,479
+240
| +0.2% | +$10K | ﹤0.01% | 2033 |
|
|
2020
Q1 | $4.33M | Sell |
137,239
-15,513
| -10% | -$819K | ﹤0.01% | 2148 |
|
|
2019
Q4 | $9.11M | Buy |
152,752
+50,621
| +50% | +$2.28M | ﹤0.01% | 2029 |
|
|
2019
Q3 | $3.74M | Sell |
102,131
-2,116
| -2% | -$83.8K | ﹤0.01% | 2418 |
|
|
2019
Q2 | $4.85M | Buy |
104,247
+1,114
| +1% | +$52.3K | ﹤0.01% | 2346 |
|
|
2019
Q1 | $4.14M | Sell |
103,133
-1,072
| -1% | -$48.1K | ﹤0.01% | 2425 |
|
|
2018
Q4 | $4.79M | Sell |
104,205
-13,591
| -12% | -$655K | ﹤0.01% | 2325 |
|
|
2018
Q3 | $5.23M | Buy |
117,796
+6,212
| +6% | +$285K | ﹤0.01% | 2387 |
|
|
2018
Q2 | $4.37M | Sell |
111,584
-30,335
| -21% | -$1.53M | ﹤0.01% | 2469 |
|
|
2018
Q1 | $10.3M | Buy |
141,919
+25,695
| +22% | +$1.89M | ﹤0.01% | 1965 |
|
|
2017
Q4 | $7.65M | Buy |
116,224
+852
| +0.7% | +$45.9K | ﹤0.01% | 2122 |
|
|
2017
Q3 | $5.78M | Buy |
115,372
+519
| +0.5% | +$25K | ﹤0.01% | 2277 |
|
|
2017
Q2 | $5.32M | Buy |
114,853
+10,250
| +10% | +$377K | ﹤0.01% | 2301 |
|
|
2017
Q1 | $3.69M | Buy |
104,603
+23,740
| +29% | +$544K | ﹤0.01% | 2486 |
|
|
2016
Q4 | $1.01M | Buy |
80,863
+19,543
| +32% | +$233K | ﹤0.01% | 3258 |
|
|
2016
Q3 | $849K | Sell |
61,320
-898
| -1% | -$10.2K | ﹤0.01% | 3261 |
|
|
2016
Q2 | $615K | Sell |
62,218
-1,395
| -2% | -$23.1K | ﹤0.01% | 3425 |
|
|
2016
Q1 | $1.07M | Buy |
63,613
+1,823
| +3% | +$29.3K | ﹤0.01% | 3011 |
|
|
2015
Q4 | $1.38M | Buy |
61,790
+1,420
| +2% | +$35.8K | ﹤0.01% | 2951 |
|
|
2015
Q3 | $1.42M | Sell |
60,370
-23,698
| -28% | -$1.49M | ﹤0.01% | 2957 |
|
|
2015
Q2 | $6.87M | Buy |
84,068
+14,662
| +21% | +$1.44M | ﹤0.01% | 2164 |
|
|
2015
Q1 | $6.43M | Sell |
69,406
-23,728
| -25% | -$1.53M | ﹤0.01% | 2180 |
|
|
2014
Q4 | $3.77M | Buy |
93,134
+34,132
| +58% | +$1.04M | ﹤0.01% | 2464 |
|
|
2014
Q3 | $1.44M | Buy |
59,002
+4,981
| +9% | +$79.2K | ﹤0.01% | 3084 |
|
|
2014
Q2 | $856K | Buy |
54,021
+2,734
| +5% | +$39.5K | ﹤0.01% | 3400 |
|
|
2014
Q1 | $775K | Buy |
51,287
+38,810
| +311% | +$602K | ﹤0.01% | 3406 |
|
|
2013
Q4 | $171K | Buy |
12,477
+1,841
| +17% | +$26.8K | ﹤0.01% | 3897 |
|
|
2013
Q3 | $200K | Buy |
+10,636
| New | +$179K | ﹤0.01% | 3796 |
|
Other funds holding ESPR
TC
WA
TH
AAM
CIEC
CCM
SWG
Bank of New York Mellon's ESPR Position: Q2 2026 in Review
Bank of New York Mellon increased its Esperion Therapeutics (ESPR) stake by 32% in Q2 2026, buying an estimated $496K and bringing the position to 732,616 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2866.
Bank of New York Mellon first reported a position in ESPR in Q3 2013 and has held it in 52 quarters since. The position peaked at $10.3M in Q1 2018. 67 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.
- Bank of New York Mellon held 732,616 shares of Esperion Therapeutics worth $2.32M as of Q2 2026.
- Bank of New York Mellon bought 177,439 Esperion Therapeutics shares in Q2 2026, an estimated $496K.
- Esperion Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2866 holding.
- Bank of New York Mellon first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 52 quarters since.
- Bank of New York Mellon's Esperion Therapeutics position peaked at $10.3M in Q1 2018.
- 67 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.